Schedule 13D ownership disclosure
Tango Therapeutics Inc
Common Stock · CUSIP: 87583X109
Event date: 2026-02-06
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Third Rock Ventures IV, L.P.Reported CIK 0001688327
Shares: 6,374,574 · Class: 4.74%
- Third Rock Ventures GP IV, L.P.Reported CIK 0001688326
Shares: 6,374,574 · Class: 4.74%
- TRV GP IV, LLCReported CIK 0001688325
Shares: 6,374,574 · Class: 4.74%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-044719
- Form type
- SCHEDULE 13D/A
- Filer
- Tango Therapeutics, Inc.
- CIK
- CIK 1819133
- Filed
- Feb 10, 2026
- Reporting period
- Feb 06, 2026
- Description
- Schedule 13D beneficial ownership